Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Prices $1.2B Senior Notes Offering

NEW YORK (GenomeWeb) – Laboratory Corporation of America today priced its offering of $1.2 billion in senior notes.

The offering consists of two tranches, a $600 million aggregate principal of 3.25 percent senior notes due in 2024, and a $600 million aggregate principal amount of 3.6 percent senior notes due in 2027. The closing of the offering is expected on Aug. 22, and LabCorp plans to use the net proceeds for general corporate purposes, including the repayment at maturity of outstanding 2.2 percent senior notes due on Aug. 23.

The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith; Wells Fargo Securities; Barclays Capital; MUFG Securities Americas; and TD Securities. The acting co-managers on the offering are Credit Suisse Securities; KeyBanc Capital Markets; PNC Capital Markets; US Bancorp Investments; BB&T Capital markets; BNY Mellon Capital Markets; Credit Agricole Securities; Fifth Third Securities; and Goldman Sachs.

In late July, LabCorp announced a deal to acquire specialty contract research organization Chiltern for about $1.2 billion in cash. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.